Raymond James Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained an 'Outperform' rating on ProQR Therapeutics (NASDAQ:PRQR), but lowered the price target from $5 to $4.

November 08, 2023 | 11:18 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ProQR Therapeutics' price target has been lowered from $5 to $4 by Raymond James, though the 'Outperform' rating is maintained.
The lowering of the price target by Raymond James could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100